CD40 and neoplasm: A clinical trial looking at the efficacy of an oncolytic adenoviral vector encoding an anti-CD40 antibody in advanced tumours, alone and in combination with systemic Pembrolizumab, has been completed and is currently awaiting results (NCT03852511).